FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients were administered intravenous doses of 0.7 to 1.3 mg/m 2 of bortezomib twice weekly.
Danish: Patienterne fik administreret intravenøse doser bortezomib på 0,7-1,3 mg/m 2 2 gange ugentligt.
English: Each carton of 2.5 mg, 3 mg or 3.5 mg Bortezomib Hospira contains a glass 10 ml vial with a rubber stopper and an aluminium seal.
Danish: Hver pakning med 2,5 mg, 3 mg eller 3,5 mg Bortezomib Hospira indeholder et 10 ml hætteglas med gummiprop og aluminiumsforsegling.
English: Bortezomib is a proteasome inhibitor.
Danish: Bortezomib er en proteasomhæmmer.
English: If you have not been treated before for multiple myeloma, and you are not suitable for blood stem cell transplantation you will receive bortezomib intravenously or subcutaneously together with two other medicines; melphalan and prednisone.
Danish: Hvis du ikke er blevet behandlet for myelomatose tidligere, og du ikke er egnet til at få transplantation med blodstamceller, vil du få bortezomib intravenøst eller subkutant samtidig med to andre lægemidler melphalan og prednison.
English: • Injection site or injection device related disorders
Danish: • Lidelser forbundet med injektionsstedet eller injektionsudstyret
English: Bortezomib Hospira therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better.
Danish: Afbryd behandling med Bortezomib Hospira, indtil toksicitetssymptomerne er svundet til grad 2 eller bedre.
English: ≥ Grade 2 PN
Danish: PN ≥ grad 2
English: The most commonly reported adverse reactions during treatment with bortezomib are nausea, diarrhoea, constipation, vomiting, fatigue, pyrexia, thrombocytopenia, anaemia, neutropenia, peripheral neuropathy (including sensory), headache, paraesthesia, decreased appetite, dyspnoea, rash, herpes zoster and myalgia.
Danish: De mest almindelige bivirkninger, der er indberettet under behandling med bortezomib, er kvalme, diarré, obstipation, opkastning, træthed, pyreksi, thrombocytopeni, anæmi, neutropeni, perifer neuropati (herunder sensorisk neuropati), hovedpine, paræstesi, nedsat appetit, dyspnø, udslæt, herpes zoster og myalgi.
English: Patients in the BDx group received four 21 day cycles, each consisting of bortezomib (1.3 mg/m2 administered intravenously twice weekly on days
Danish: Patienterne i BDx-gruppen fik 4 cyklusser af 21-dages varihed, hver bestående af bortezomib (1,3 mg/m administreret intravenøst
English: Dose adjustments for combination therapy for patients with progressive multiple myeloma For Bortezomib Hospira dosage adjustments for combination therapy follow dose modification guidelines described under monotherapy above.
Danish: Dosisjustering ved kombinationsbehandling for patienter med progressiv myelomatose Dosisjustering af Bortezomib Hospira ved kombinationsbehandling skal følge de retningslinjer, der er beskrevet under monoterapi ovenfor.
English: VDDx=vincristine, doxorubicin, dexamethasone; BDx=bortezomib, dexamethasone; TDx=thalidomide, dexamethasone;
Danish: VDDx=vincristin, doxorubicin, dexamethason; BDx=bortezomib, dexamethason; TDx=thalidomid, dexamethason;
English: f n (%) nCR n (%) CR+PR
Danish: nCR n (%) CR+PR
English: Four treatment cycles of this combination are administered.
Danish: Der administreres fire behandlingscyklusser med denne kombination.
English: NOS=not otherwise specified * Grouping of more than one MedDRA preferred term.
Danish: * Gruppering af mere end én ”foretrukken term” iht.
English: #, Dermatitis*, Hair disorder*, Petechiae, Ecchymosis, Skin lesion, Purpura, Skin mass*, Psoriasis, Hyperhidrosis, Night sweats, Decubitus ulcer
Danish: #, dermatitis*, hårsygdom*, petekkier, ekkymose, hudlæsion, purpura, udfyldning i huden*, psoriasis, hyperhidrose, nattesved, decubitus
English: • Inject the solution subcutaneously, under a 45-90°angle.
Danish: • Injicér opløsningen subkutant i en vinkel på 45-90°.
English: • General ill feeling, pain, vertigo, light-headedness, a feeling of weakness or loss of consciousness
Danish: • Generel følelse af at være syg, smerter, svimmelhed, ørhed, en følelse af afkræftelse eller bevidsthedstab
English: Clinical efficacy in relapsed or refractory multiple myeloma The safety and efficacy of bortezomib (injected intravenously) were evaluated in 2 studies at the recommended dose of 1.3 mg/m2: a Phase III randomised, comparative study (APEX), versus dexamethasone (Dex), of 669 patients with relapsed or refractory multiple myeloma who had received 1-3 prior lines of therapy, and a Phase II single-arm study of 202 patients with relapsed and refractory multiple myeloma, who had received at least 2 prior lines of treatment and who were progressing on their most recent treatment.
Danish: Klinisk virkning ved recidiverende eller refraktær myelomatose Sikkerheden og effekten ved bortezomib (som intravenøs injektion) blev undersøgt i 2 forsøg med den anbefalede dosis på 1,3 mg/m2: et randomiseret, komparativt fase III-forsøg (APEX), vs. dexamethason (Dex) med 669 patienter med recidiverende eller refraktær myelomatose, som havde fået 1-3 tidligere behandlinger, og et fase II-forsøg med en enkelt gruppe med 202 patienter med recidiverende eller refraktær myelomatose, som havde fået mindst 2 tidligere behandlinger, og som i deres seneste behandlingsregime havde oplevet progression.
English: • If local injection site reactions occur following Bortezomib Hospira injection subcutaneously, either a less concentrated Bortezomib Hospira solution (1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.
Danish: • I tilfælde af lokale reaktioner på injektionsstedet efter subkutan injektion af Bortezomib Hospira anbefales det enten at administrere en mindre koncentreret Bortezomib Hospira-opløsning (1 mg/ml i stedet for 2,5 mg/ml) subkutant eller at skifte til intravenøs administration.
English: Table 4: Posology for Bortezomib Hospira combination therapy for patients with previously untreated multiple myeloma eligible for haematopoietic stem cell transplantation B+Dx
Danish: Tabel 4: Dosering for kombinationsbehandling med Bortezomib Hospira til patienter med tidligere ubehandlet myelomatose, som er egnede til hæmatopoietisk stamcelletransplantation B+Dx
English: Each carton of 1 mg Bortezomib Hospira contains a glass 5 ml siliconised vial with a rubber stopper and an aluminium seal.
Danish: Hver pakning med 1 mg Bortezomib Hospira indeholder et 5 ml silikonebehandlet hætteglas med gummiprop og aluminiumsforsegling.
English: ≥ Grade 3 PN
Danish: PN ≥ grad 3
English: • to report any adverse event, or medication error experienced with the administration of Bortezomib Hospira 1 mg, 2.5 mg, 3 mg and 3.5 mg.
Danish: • Information om, at eventuelle bivirkninger eller medicineringsfejl i forbindelse med administration af Bortezomib Hospira 1 mg, 2,5 mg, 3 mg og 3,5 mg bør indberettes.
English: In study LYM-3002, colony stimulating factor support was given to 78% of patients in the BR-CAP arm and 61% of patients in the R-CHOP arm.
Danish: I forsøget LYM-3002 fik 78% af patienterne i BR-CAP-gruppen og 61% af patienterne i RCHOP-gruppen understøttende behandling med kolonistimulerende faktor.
English: B=bortezomib; BDx=bortezomib, dexamethasone; VDDx=vincristine, doxorubicin, dexamethasone; VGPR=very good partial response; PR=partial response; OR=odds ratio.
Danish: B = bortezomib; BDx = bortezomib, dexamethason; VDDx = vincristin, doxorubicin, dexamethason; VGPR = meget godt partielt respons; PR = partielt respons; OR = odds ratio.
English: Intent to Treat (ITT) population p-value from the stratified log-rank test; analysis by line of therapy excludes stratification for therapeutic history; p < 0.0001 Response population includes patients who had measurable disease at baseline and received at least 1 dose of study medicinal product.
Danish: Intent to Treat (ITT) -population p-værdi fra den stratificerede log-rank-test; analyse ud fra behandling udelukker stratifikation ifølge tidligere behandling; p < 0,0001
English: Aseptic technique must be strictly observed throughout the handling of Bortezomib Hospira, since it contains no preservative.
Danish: DET ER YDERST VIGTIGT, AT DER ANVENDES ASEPTISK TEKNIK UNDER HÅNDTERINGEN AF BORTEZOMIB HOSPIRA, DA DET IKKE INDEHOLDER KONSERVERINGSMIDDEL.
English: Blood gases abnormal*, Electrocardiogram abnormalities (inc QT prolongation)*, International normalised ratio abnormal*, Gastric pH decreased, Platelet aggregation increased, Troponin I increased, Virus identification and serology*, Urine analysis abnormal*
Danish: QT-forlængelse)*, unormal INR (international normalised ratio)*, nedsat gastrisk pH, øget thrombocytaggregation, forhøjet troponin I, identifikation og serologisk test af virus*, unormal urinprøve*
English: Peripheral embolism, Lymphoedema, Pallor, Erythromelalgia, Vasodilatation, Vein discolouration, Venous insufficiency
Danish: Sjælden Perifer emboli, lymfødem, bleghed, erythromelalgi, vasodilatation, misfarvning af vener, veneinsufficiens
English: Secondary efficacy endpoints included post-transplant response rates (CR+nCR, CR+nCR+VGPR+PR), Progression Free Survival and Overall Survival.
Danish: (CR+nCR, CR+nCR+VGPR+PR), progressionsfri overlevelse og samlet overlevelse.
English: • Infection or inflammation of the stomach and intestines
Danish: • Infektion eller inflammation (betændelseslignende tilstand) i mave eller tarme
English: There are no studies on the use of bortezomib in elderly patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Danish: Der foreligger ingen forsøg af anvendelse af bortezomib til ældre patienter med tidligere ubehandlet myelomatose, som er egnede til højdosis kemoterapi med hæmatopoietisk stamcelletransplantation.
English: Some of these include difficulty breathing, shortness of breath, shortness of breath without exercise, breathing that becomes shallow, difficult or stops, wheezing
Danish: Nogle af disse sygdomme indebærer vejrtrækningsbesvær, stakåndethed, stakåndethed uden fysiske udfoldelser, overfladisk eller besværet vejrtrækning eller stop i vejrtrækningen, hvæsende vejrtrækning
English: A drug-drug interaction study assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 35% (CI90% [1.032 to 1.772]) based on data from 12 patients.
Danish: I et lægemiddelinteraktionsforsøg med undersøgelse af virkningen af ketoconazol, en potent CYP3A4hæmmer, på bortezomibs farmakokinetik (som intravenøs injektion) ses en gennemsnitlig stigning i bortezomibs AUC på 35% (CI90% [1,032 til 1,772]), baseret på data fra 12 patienter.
English: Type I glass 5 ml siliconised vial with a rubber stopper and an aluminium seal containing 1 mg bortezomib.
Danish: Silikonebehandlet hætteglas på 5 ml (type I-glas) med gummiprop og aluminiumsforsegling, der indeholder 1 mg bortezomib.
English: Four treatment cycles of this combination therapy are administered.
Danish: Der administreres 4 behandlingscyklusser af denne kombinationsbehandling.
English: Your doctor may change the dose and total number of treatment cycles, depending on your response to the treatment on the occurrence of certain side effects and on your underlying conditions (e.g. liver problems).
Danish: Det afhænger af, hvordan du reagerer på behandlingen, om du får bestemte bivirkninger, og hvilke sygdomme, du lider af (f.eks. leverproblemer).
English: Neuropathies*, Motor neuropathy*, Loss of consciousness (inc syncope), Encephalopathy*, Peripheral sensorimotor neuropathy, Dizziness*, Dysgeusia*, Autonomic neuropathy Uncommon Autonomic nervous system imbalance
Danish: synkope), encefalopati*, perifer sensomotorisk neuropati, svimmelhed*, dysgeusi*, autonom neuropati Ikke almindelig Ubalance i det autonome nervesystem
English: • Low blood pressure, sudden fall of blood pressure on standing which may lead to fainting
Danish: • Lavt blodtryk, pludseligt fald i blodtrykket, når du rejser dig.
English: When bortezomib is given alone, you will receive 4 doses of bortezomib intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a 10-day ‘rest period' without treatment.
Danish: Hvis bortezomib gives alene, vil du få 4 doser bortezomib intravenøst eller subkutant på dag 1, 4, 8 og 11 efterfulgt af en pause på 10 dage uden behandling.
English: The effect of hepatic impairment on the pharmacokinetics of bortezomib was assessed in a Phase I study during the first treatment cycle, including 61 patients primarily with solid tumors and varying degrees of hepatic impairment at bortezomib doses ranging from 0.5 to 1.3 mg/m
Danish: Effekten af nedsat leverfunktion på bortezomibs farmakokinetik i doseringsintervallet 0,5-1,3 mg/m blev undersøgt i et fase I-forsøg i den første behandlingscyklus hos 61 patienter med primært solide tumorer og nedsat leverfunktion i varierende grad.
English: • Platelet counts should be ≥ 70 x 10 9/l and the absolute neutrophils count should be ≥ 1.0 x 10 9/l
Danish: 9/l, og absolut neutrofiltal skal være ≥ 1,0 x 10
English: • Shingles (localized including around the eyes or spread across the body)
Danish: • helvedesild (lokaliseret, for eksempel omkring øjnene eller spredt over hele kroppen)
English: Very Common Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia* Common
Danish: Meget almindelig Perifer sensorisk neuropati, dysæstesi*, neuralgi* Almindelig
English: Uncommon Acute respiratory distress syndrome, Pulmonary embolism, Pneumonitis, Pulmonary hypertension, Pulmonary oedema (inc acute)
Danish: Ikke almindelig Akut respiratorisk distress syndrom, lungeemboli, pneumonitis, pulmonal hypertension, lungeødem (inkl.
English: One single autologous stem cell transplant was received by 105 (81%) patients and 78 (61%) patients in the BTDx and TDx groups, respectively.
Danish: 105 (81%) og 78 (61%) patienter i henholdsvis BTDx- og TDx-gruppen fik en enkelt autolog stamcelletransplantation.
English: Patients in the BR-CAP treatment arm received bortezomib (1.3 mg/m2; on days 1, 4, 8, 11, rest period days 12-21), rituximab
Danish: Patienterne i BR-CAP-gruppen fik bortezomib (1,3 mg/m på dag 1, 4, 8, 11, pause dag 12-21), rituximab 375 mg/m 2 i.v.
English: Do not use Bortezomib Hospira - if you are allergic to bortezomib, boron or to any of the other ingredients of this medicine (listed in section 6) - if you have certain severe lung or heart problems.
Danish: Brug ikke Bortezomib Hospira - hvis du er allergisk over for bortezomib, bor eller et af de øvrige indholdsstoffer i Bortezomib
English: Dyspnoea*, Cough*, Hiccups
Danish: Dyspnø*, hoste*, hikke
English: Muscle spasms*, Musculoskeletal pain*, Pain in extremity
Danish: Muskelspasmer*, muskuloskeletale smerter*, ekstremitetssmerter
English: Bortezomib Hospira therapy should be withheld until symptoms of the toxicity have resolved to Grade 1 or baseline.
Danish: Afbryd behandling med Bortezomib Hospira, indtil toksicitetssymptomerne er svundet til grad 1 eller niveauet ved baseline.
English: • different reconstitution requirements for Bortezomib Hospira 1 mg, 2.5 mg, 3 mg and 3.5 mg IV or
Danish: • Information om, at kravene til rekonstitution af Bortezomib Hospira 1 mg, 2,5 mg, 3 mg og 3,5
English: #, Bronchospasm, Chronic obstructive pulmonary disease*, Hypoxaemia*, Respiratory tract congestion*, Hypoxia, Pleurisy*, Hiccups, Rhinorrhoea, Dysphonia, Wheezing
Danish: #, bronkospasme, kronisk obstruktiv lungesygdom*, hypoksæmi*, luftvejskongestion*, hypoksi, pleuritis*, hikke, rinoré, dysfoni, hvæsende vejrtrækning
English: If local injection site reactions occur following Bortezomib Hospira subcutaneous injection, either a less concentrated Bortezomib Hospira solution (Bortezomib Hospira to be reconstituted to 1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.
Danish: Hvis der opstår lokale reaktioner på injektionsstedet efter en subkutan injektion af Bortezomib Hospira, bør det enten gives i en lavere koncentration (Bortezomib Hospira rekonstitueres til 1 mg/ml i stedet for 2,5 mg/ml), eller der bør skiftes til intravenøs injektion.
English: Two randomised, open-label, multicenter Phase III trials (IFM-2005-01, MMY-3010) were conducted to demonstrate the safety and efficacy of bortezomib in dual and triple combinations with other chemotherapeutic agents, as induction therapy prior to stem cell transplantation in patients with previously untreated multiple myeloma.
Danish: Patienter, som er egnede til stamcelletransplantation Der blev gennemført 2 randomiserede, åbne fase III-multicenter-forsøg (IFM-2005-01, MMY-3010) til påvisning af bortezomibs sikkerhed og effekt i dobbelte og tredobbelte kombinationer med andre cytostatika som induktionsterapi forud for stamcelletransplantation hos patienter med tidligere ubehandlet myelomatose.
English: In B-ALL patients with relapse 18-36 months from diagnosis (n = 33) the CR rate was 79% (95% CI: 61, 91) and the 4-month event free survival rate was 73% (95% CI: 54, 85).
Danish: Hos B-ALL-patienter med recidiv inden for 18-36 måneder efter diagnosticering (n=33) var CR-raten 79% (95% CI: 61-91), og den hændelsesfrie overlevelsesrate efter 4 måneder var 73% (95% CI: 54, 85).
English: When bortezomib is given together with pegylated liposomal doxorubicin, you will receive bortezomib intravenously or subcutaneously as a 21-day treatment cycle and pegylated liposomal doxorubicin 30 mg/m is given on day 4 of the bortezomib 21-day treatment cycle as an intravenous infusion after the bortezomib injection.
Danish: Hvis bortezomib gives sammen med pegyleret liposomal doxorubicin, får du bortezomib intravenøst eller subkutant i en 21-dages behandlingscyklus, og pegyleret liposomal doxorubicin gives i en dosis på 30 mg/m2 på dag 4 i den 21-dages behandlingscyklus med bortezomib som en intravenøs infusion efter injektionen af bortezomib.
English: Nine treatment cycles of this combination therapy are administered.
Danish: Der gives 9 behandlingscyklusser med denne kombination.
English: • Joint or muscle stiffness, sense of heaviness, pain in your groin
Danish: • Stivhed i led eller muskler, følelse af tunghed, smerter i lysken
English: If you are given bortezomib together with other medicines for the treatment of mantle cell lymphoma the side effects you may get are listed below:
Danish: De bivirkninger, du kan få, hvis du får bortezomib sammen med andre lægemidler til behandling af mantle-celle-lymfom, er angivet nedenfor:
English: 27.0 mo (24.7, 31.1) 19.2 mo (17.0, 21.0)
Danish: (24,7; 31,1) 19,2 mdr.
English: The CR rate in first-relapsed T-cell ALL patients (n = 22) was 68% (95% CI: 45, 86) and the 4-month event free survival rate was 67% (95% CI: 42, 83).
Danish: CR-raten hos patienter med første recidiv af T-celle-ALL (n=22) var 68% (95% CI: 45-86), og den hændelsesfrie overlevelsesrate efter 4 måneder var 67% (95% CI: 42, 83).
English: Serious adverse reactions uncommonly reported during treatment with bortezomib include cardiac failure, tumour lysis syndrome, pulmonary hypertension, posterior reversible encephalopathy syndrome, acute diffuse infiltrative pulmonary disorders and rarely autonomic neuropathy.
Danish: Alvorlige, ikke almindelige bivirkninger, der er indberettet under behandling med bortezomib, omfatter hjerteinsufficiens, tumorlysesyndrom, pulmonal hypertension, posteriort reversibelt encefalopatisyndrom samt akutte, diffuse, infiltrative lungesygdomme.
English: B=bortezomib; BTDx=bortezomib, thalidomide, dexamethasone; TDx=thalidomide, dexamethasone; PR=partial response;
Danish: B = bortezomib; BTDx = bortezomib, thalidomid, dexamethason; TDx = thalidomid, dexamethason; PR = partielt respons;
English: When rituximab is used in combination with Bortezomib Hospira, HBV screening must always be performed in patients at risk of infection with HBV before initiation of treatment.
Danish: Reaktivering og infektion af hepatitis B-virus (HBV) Hvis rituximab anvendes i kombination med Bortezomib Hospira, skal patienter med risiko for HBVinfektion altid screenes for HBV, inden behandlingen startes.
English: Very rare cases with unknown causality of John Cunningham (JC) virus infection, resulting in PML and death, have been reported in patients treated with bortezomib.
Danish: Der er hos patienter behandlet med bortezomib indberettet meget sjældne tilfælde af John Cunningham-virus (JC-virus), der førte til PML og dødsfald.
English: What Bortezomib Hospira looks like and contents of the pack Bortezomib Hospira powder for solution for injection is a white to off-white cake or powder.
Danish: Bortezomib Hospira pulver til injektionsvæske, opløsning, er en hvid til offwhite masse eller et hvidt til offwhite pulver.
English: Bortezomib powder has to be dissolved before administration.
Danish: Bortezomib-pulveret skal opløses, før det gives.
English: In B-ALL patients with relapse within 18 months of diagnosis (n = 27) the CR rate was 67% (95% CI: 46, 84); the 4-month event free survival rate was 44% (95% CI: 26, 62).
Danish: Hos B-ALL-patienter med recidiv inden for 18 måneder efter diagnosticering (n=27) var CR-raten 67% (95% CI: 46-84), og den hændelsesfrie overlevelsesrate efter 4 måneder var 44% (95% CI: 26, 62).
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Danish: FREMSTILLER(E) ANSVARLIG(E) FOR BATCHFRIGIVELSE
English: Respiratory failure, Acute respiratory distress syndrome, Apnoea, Pneumothorax, Atelectasis, Pulmonary hypertension, Haemoptysis, Hyperventilation, Orthopnoea, Pneumonitis, Respiratory alkalosis, Tachypnoea, Pulmonary fibrosis, Bronchial disorder*, Hypocapnia*, Interstitial lung disease, Lung infiltration, Throat tightness, Dry throat, Increased upper airway secretion, Throat irritation, Upperairway cough syndrome
Danish: Sjælden Respirationssvigt, akut respiratorisk distress syndrom, apnø, pneumothorax, atelektase, pulmonal hypertension, hæmoptysis, hyperventilation, ortopnø, pneumonitis, respirationsalkalose, takypnø, lungefibrose, bronkiesygdom*, hypokapni*, interstitiel lungesygdom, lungeinfiltration, sammensnøring af halsen, tørhed i halsen, øget sekret i de øvre luftveje, halsirritation, hostesyndrom i øvre luftveje
English: Withhold Bortezomib Hospira treatment until symptoms of toxicity have resolved.
Danish: Afbryd behandlingen med Bortezomib Hospira, indtil toksicitetssymptomerne er forsvundet.
English: • dosing instructions and examples: how to calculate the body surface area of a patient and the volume of reconstituted Bortezomib Hospira (both IV and SC use) required for different body surface areas.
Danish: • Vejledning i dosering med eksempler: Beregning af patientens legemsoverfladeareal og det nødvendige volumen rekonstitueret Bortezomib Hospira (både til i.v.
English: RR (Post-induction) *CR+nCR
Danish: RR (efter induktion) *CR+nCR
English: Justification for not including Braille accepted.
Danish: Fritaget for krav om brailleskrift.
English: 1 mg/m 2, or from 1 mg/m 2 to 0.7 mg/m 2).
Danish: 1,0 mg/m 2; 1,0 mg/m reduceret til 0,7 mg/m 2).
English: Bortezomib is used for the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously treated and for whom blood stem cell transplantation is unsuitable.
Danish: Bortezomib bruges til behandling af mantle-celle-lymfom (en type kræft, som påvirker lymfeknuderne) i kombination med lægemidlerne rituximab, cyclophosphamid, doxorubicin og prednison, til patienter på 18 år og derover, hvis sygdom ikke tidligere er blevet behandlet, og som ikke er egnede til at gennemgå en transplantation af blodstamceller.
English: What Bortezomib Hospira contains
Danish: Bortezomib Hospira indeholder: